Dabrafenib and Trametinib Treatment for Erdheim-Chester Disease With Brain Stem Involvement
Open Access
- 4 July 2018
- journal article
- case report
- Published by Elsevier BV in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 2 (3), 303-308
- https://doi.org/10.1016/j.mayocpiqo.2018.05.001
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)Blood, 2017
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialThe Lancet Oncology, 2015
- Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case reportBMC Research Notes, 2015
- Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibThe New England Journal of Medicine, 2015
- Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin LesionsPLOS ONE, 2013
- Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain MetastasesThe Journal of pharmacology and experimental therapeutics, 2012
- Dabrafenib and its potential for the treatment of metastatic melanomaDrug Design, Development and Therapy, 2012
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytosesBlood, 2012
- CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patientsBlood, 2011